Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Hairy cell leukemia treatment strategies: A real-world multicenter experience

James Fradin, Lisa Rein, Aniko Szabo, Karen-Sue Carlson, Talha Badar, Troy Holden, Shiv Shah, Annie Im, Anand Patel, Ehab Atallah

Blood (2025) 146 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2025-1802

Published: 2025

Journal Articles

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes

Adam Kidwell, Karolina Lungova, Aniko Szabo, Emilie Aschenbrenner, Timothy Schieber, Forat Lutfi, Wilder Widman, Austin Quick, Ashley Dunton, Bhagirathbhai Dholaria, Olalekan Oluwole, Rita Ahmad, Seth Maliske, Caitlin Guzowski, Scott Solomon, Melissa Babcook, Nathan Denlinger, Nirav Shah

Blood (2025) 146 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2025-6302

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Blood (2025) 146 (Supplement 1): 170.

https://doi.org/10.1182/blood-2025-170

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL

Nirav Shah, Maria Poimenidou, Adam Kidwell, Aniko Szabo, Tyce Kearl, Bryon Johnson, Anthony Stillwell, Sumana Devata, Kaitlin Annunzio, Rimas Orentas, Walter Longo, Timothy Fenske, Peiman Hematti, Michael Dwinell, Mehdi Hamadani

Blood (2025) 146 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2025-2401

Published: 2025

Journal Articles

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Christopher Fletcher, Aniko Szabo, Sumana Devata, Vaishalee Kenkre, Priyanka Pophali, Luke Zurbriggen, Julie Chang, Katina Deshong, Mitch Howard, Mariah Endres, Joel Pollen, Esta Konkol, Walter Longo, Mehdi Hamadani, Timothy Fenske, Saurabh Rajguru, Nirav Shah

Blood (2025) 146 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2025-1964

Published: 2025

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Kristine Broge-Reynen, Emily Giever, Aniko Szabo, Ryan Conrardy, Nicole M Held, Laura C. Michaelis, Lyndsey Runaas, Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson, Ravi Kishore Narra, Sumana Devata, Sheila Swartz, Valarie Ehrlich, Mary Rodgers, Allison Johnson, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2024-208834

Published: 2024

Journal Articles

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Gulrayz Ahmed, Amer Al Homssi, Ramsha Ahmed, Walter Longo, Nirav N. Shah, Lyndsey Runaas, Marcelo C. Pasquini, Timothy S. Fenske, Lisa E Rein, Aniko Szabo, Mehdi Hamadani, Sameem Abedin

Blood (2024) 144 (Supplement 1): 7346.

https://doi.org/10.1182/blood-2024-209225

Published: 2024

Journal Articles

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Nirav N. Shah, Aniko Szabo, Tyce Kearl, Dina Schneider, Walter Longo, Bryon D. Johnson, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske

Blood (2024) 144 (Supplement 1): 3448.

https://doi.org/10.1182/blood-2024-200899

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

Chimeric Antigen Receptor T Cells (CAR-T) Vs. Bispecific Antibody (BsAb) Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): A Systematic Review and Metaanalysis

Hayley Vandenboom, Aniko Szabo, Othman S Akhtar, Ravi Narra, Meera Mohan, Anita D'Souza, Marcelo C. Pasquini, Binod Dhakal

Blood (2024) 144 (Supplement 1): 6911.

https://doi.org/10.1182/blood-2024-200442

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2023-173954

Published: 2023

Journal Articles

The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 758.

https://doi.org/10.1182/blood-2023-186697

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hairy cell leukemia treatment strategies: A real-world multicenter experience

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Chimeric Antigen Receptor T Cells (CAR-T) Vs. Bispecific Antibody (BsAb) Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): A Systematic Review and Metaanalysis

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only